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Abstract: Allergic diseases have greatly increased in industrialized countries. About 30% of 
people suffer from allergic symptoms and 40%–80% of them have symptoms in the eyes. Atopic 
conjunctivitis can be divided into seasonal allergic conjunctivitis (SAC) and perennial allergic 
conjunctivitis  (PAC).  The  treatment  of  SAC  is  simple;  antihistamines,  anti-inflammatory 
agents, or chromoglycate. In severe cases of SAC, subcutaneous or sublingual immunotherapy 
is helpful. PAC needs longer therapy, often year round, with mast cell stabilizers, antihistamines, 
and sometimes local steroids. Atopic keratoconjunctivitis is a more severe disease showing 
chronic blepharitis often connected with severe keratitis. It needs, in many cases, continuous 
treatment of the lid eczema and keratoconjunctivitis. Blepharitis is treated with tacrolimus 
or pimecrolimus ointment. Conjunctivitis additionally needs corticosteroids and, if needed, 
cyclosporine A (CsA) drops are administered for longer periods. Basic conjunctival treatment 
is with mast cell-stabilizing agents and in addition, antihistamines are administered. Vernal 
keratoconjunctivitis is another chronic and serious allergic disease that mainly affects children 
and young people. It is a long-lasting disease which commonly subsides in puberty. It demands 
intensive therapy often for many years to avoid serious complicating corneal ulcers. Treatment 
is mast cell-stabilizing drops and additionally antihistamines. In relapses, corticosteroids are 
needed. When the use of corticosteroids is continuous, CsA drops should be used, and in 
relapses, corticosteroids should be used additionally. Nonallergic eosinophilic conjunctivitis 
(NAEC) is a less known, but rather common, ocular disease. It affects mostly middle-aged 
and older women. The eye symptoms of NAEC are largely similar to those seen in chronic 
allergic conjunctivitis. Basic therapy is mast cell-stabilizing drops. Eosinophilic inflammation 
needs additional corticosteroids. In severe cases, CsA drops are recommended. Antihistamines 
should be avoided. It is important to recognize the different forms of allergic ocular diseases 
and to start the treatment early and intensively enough to avoid chronicity of the disease and 
accompanying tissue destruction.
Keywords: allergic conjunctivitis, allergic blepharitis, atopic keratoconjunctivitis, eosinophils, 
vernal keratoconjunctivitis
Introduction
Approximately one-third of the population is affected by some form of allergic disease 
worldwide,1 and ocular allergic symptoms are estimated to be present in 40%–80% 
of the affected individuals.2 The prevalence is greater in Western countries than in 
Asia3 or Africa.
Allergic eye inflammation is a localized allergic condition that is frequently 
associated with rhinitis and occasionally with asthma but often observed as the only or Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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prevalent allergic sensitization. The symptoms and signs can 
manifest as conjunctivitis, blepharitis, blepharoconjunctivitis, 
or keratoconjunctivitis. The eye becomes red and itchy; there 
occurs lacrimation and slight discharge.
The allergic eye symptoms are mostly associated with 
atopy. The early phase reflects mast cell activation of 
allergic inflammation, whereas the late phase reaction is 
characterized by recruitment of inflammatory cells to the 
site of allergic inflammation. Initially, the visual acuity is 
usually normal. However, in some severe forms of allergic 
conjunctivitis and vernal keratoconjunctivitis (VKC), there 
may be visual impairment or change secondary to corneal 
damage or corneal curvature change.4 In the age group below 
14 years, 44.7% of children with atopy had allergic rhinitis 
and 61% of them had conjunctivitis but only 5% presented 
with conjunctivitis alone.5 Chronic allergic eye disease 
should be differentiated from the nonallergic eosinophilic 
conjunctivitis (NAEC).6,7
The main goal of the treatment of an allergic eye 
disease is to reduce the inflammation early and to prevent 
complications, which can threaten vision or cause dry eye. In 
some cases, the active therapy can prevent the development 
of allergic rhinosinusitis or even asthma.8
In this article, we present a new understanding of the 
pathomechanisms of ocular allergy and new treatment 
modalities that target the pathomechanisms of allergic eye   
diseases.
Etiology
Seasonal allergic conjunctivitis (SAC) and perennial aller-
gic conjunctivitis (PAC) are caused by immunoglobulin E 
(IgE)-mediated environmental airborne allergens, such as 
grass and tree pollens, mites, molds, and animal dander. 
The minority of allergic eye diseases are of cell-mediated 
or mixed type, which may manifest solely as blepharitis, 
blepharoconjunctivitis, or keratoconjunctivitis. The usual 
causes of the cell-mediated type are cosmetics, nickel, or 
topical eye medication.
The exact incidences of work-related allergic eye 
diseases are lacking. There is a wide spectrum of organic and 
inorganic materials that can cause allergies. In most cases, 
they are linked to asthma, rhinitis, or dermatitis. Some work-
ers may have only occupational eye symptoms.9
Pathomechanisms
The immediate types, SAC and PAC, are IgE-mediated 
diseases. The peaks of ocular signs and symptoms are related 
to histamine release from specifically activated mast cells 
after allergen exposure.10 Mast cells contain, for example, 
histamine and tryptase. De novo synthesis of other mediators 
like leukotriens and prostaglandins also immediately begins. 
Histamine and other mediators like neurotrophins are 
responsible for itching.11,12 Activation of vascular endothelial 
cells and fibroblasts by a single mast cell degranulation can 
mount a cascade of proinflammatory events that amplify the 
clinical inflammation.13 The influence of different mediators, 
histamine, tryptase, prostaglandins, and leukotrienes,4 is 
strongest after 10–15 min. The chemotactic factors released 
by mast cells are responsible for accumulation of eosinophils 
and neutrophils at the site of allergic inflammation. 
Eosinophils contain granules in which preformed cytokines 
are rapidly secreted depending on the cytokine stimuli, Th1 
(interleukin [IL]-12, IL-27, and interferon [IFN]-γ), and Th2 
(IL-4 and IL-13).14
Lymphocytes, both T and B cells, are important cells in 
allergic reactions. These are divided into CD4+ helper T cells 
(Th) and CD8+ killer T cells (Tk). CD4+ Th cells are com-
monly divided into regulatory T (Treg) and T helper (Th) 
cells. Treg cells are defined as CD4+ T cells, which may 
suppress potentially deleterious activities of Th cells. Treg 
cells are very important, for example, in the suppression of 
allergic reactions.15 Th1-type T helper cells are activated in 
the classic delayed-type hypersensitivity reaction and in some 
autoimmune diseases. The activation of Th2 cells leads to 
the anaphylactic type of hypersensitivity reaction.14 T cells 
start and regulate the immune response. IL-4 has an essential 
role in differentiating Th cells to Th2 cells. The activated Th 
cells regulate the maturation of B lymphocytes to mature 
antibody-producing B cells and plasma cells. The maturation 
of B lymphocytes to IgE-producing cells requires in addition 
to IL-4 a direct contact between pre-B and Th cells.
The prerequisite for the immune reaction is that the antigen 
must be recognized and presented to the cells, which are 
responsible for the development of the immune response.14 
The antigen-presenting cells (APCs) in the conjunctiva are the 
Langerhans cells (LCs), which present the antigen to allergen-
specific T lymphocytes (CD4+ T cells). These secrete Th2 
cytokines such as IL-4 (for IgE synthesis) and IL-5 (eosino-
philic growth factor). When re-exposures to allergen occurs, it 
activates Th2 cells to express Th2 cytokines. Simultaneously, 
it cross-links IgE, which is affixed to mast cell high-affinity 
receptors, and induces mast cell degranulation.15
The APCs have an important role, both direct and indirect, 
to control the expansion and function of T cells. They also Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
151
Treatment of ocular allergies
initiate a CD8 cytotoxic T-cell response, which is responsible 
for various forms of autoimmunity and transplant rejection.16 
Antigen (Ag)-specific T cells initiate the eosinophilic infiltra-
tion in the conjunctiva because allergic conjunctivitis is an 
Ag-specific disease and eosinophils do not have Ag-specific 
receptors.17
In the cell-mediated type of reaction (delayed type 
or type IV), T cells recognize the antigen and start the 
inflammatory reaction. Typical delayed-type reactions 
are contact dermatoconjunctivitis and Mantoux (tubercu-
lin) reaction. Macrophages activated by Th cells destroy 
intracellular bacteria, but they also cause other delayed 
inflammatory reactions including the contact hypersensitiv-
ity of the skin and tuberculin reaction. These reactions reach 
their maximum in 24–72 h.
Diagnostics
A good patient history and clinical examination are essen-
tial and can solve the nature of the eye disease in many 
cases. When the diagnosis is not clear, some laboratory 
examinations are needed. When an infection could be 
possible, bacterial and viral specimens are taken. By using 
the conjunctival brush cytology, it is possible to see, for 
example, typical epithelial changes in dry eyes. The spectrum 
of inflammatory cells can reveal the nature of the inflam-
mation. An allergic inflammation is especially suspected if 
eosinophils are seen.
Tear fluid IgE can be measured. The local production is 
evident, but it shows only the free IgE, which is not tissue 
bound.
Determination of inflammatory mediators like eosinophilic 
cationic proteins and cytokines may be helpful, but the 
determination is difficult and time consuming and thus not 
suitable for everyday practice.
When the patient history is clear and the symptoms are 
typical for SAC, the allergy tests are usually not needed. In 
suspected cases, where diagnosis is not clear, a basic skin prick 
test or specific serum IgE-determinations (ImmunoCAP®; 
Phadia, Uppsala, Sweden) are recommended. A good allergy 
examination, especially in children, is needed. The total 
serum IgE itself is not enough to prove ocular allergy.
When the patient has also a suspected allergic blepharitis, 
the epicutan tests should be done. If contact allergy to 
eyedrops is suspected, an epicutan test should be done with 
the drops used (sometimes also as prick test).
When there is a strong doubt about allergy or an 
immunotherapy is planned, an ophthalmic challenge test can 
be made. It should be done with standardized water-soluble 
allergen extracts (SQ-quality; ALK-Abello, Copenhagen, 
Denmark). The test should be done with the patient always 
blinded in one eye and the diluent as placebo in the other 
eye.18 In occupational allergy, some substances can be tested, 
but in most cases, the direct tests are not possible.
Treatment targets  
the pathomechanisms  
of ocular allergies
Steroid preparations, antihistamines, and mast cell-stabilizing 
drugs have long been the mainstay of the therapy. In mild 
conditions, antihistamines and mast cell-stabilizing drugs are 
sufficient. Chronic, severe allergic eye disorders like VKC 
and atopic blepharoconjunctivitis (ABC) are the challenge 
for treatment. To avoid the serious ocular side effects of 
long-term corticosteroid treatment, we have, nowadays, the 
opportunity to use a new class of anti-inflammatory agents 
in corticosteroid replacing therapy, namely, calcineurin (Cn) 
inhibitors.
Cn has an important role in the immune response. 
Inflammatory cells play a role in producing and maintaining 
skin inflammation in atopic dermatitis. They include T cells, 
mast cells, basophils, eosinophils, and LCs. Antigen presenta-
tion by LCs leads to activation of T cells. The high-affinity 
receptor for IgE (FcεR1) on the surface of LCs binds peptide 
antigens by means of free IgE present in the inflammatory 
infiltrate. T cells are activated through a calcium-dependent 
pathway in which Cn dephosphorylates the nuclear factor of 
activated T cell protein (NF-ATp). NF-ATp then migrates 
to the T cell, where it leads to the transcription of IL-2 and 
other cytokines. Besides the role of Cn in T cells, Cn plays 
a role in various tissues and also in the skin.19–22
Cn inhibitors are capable of inducing local immunosup-
pression. Cn is the target of the immunosuppressive drugs 
cyclosporine A (CsA), tacrolimus (Trl), and pimecrolimus 
(Prl). The Cn inhibitors CsA, Trl, and Prl are used for the treat-
ment of dermatological diseases, such as psoriasis and atopic 
eczema.20,22 CsA is also effective in controlling ocular allergic 
inflammation by blocking Th2-lymphocyte proliferation and 
IL-2 production. It also reduces eosinophils’ chemotaxis via 
inhibition of IL-5 production. Earlier studies have shown 
that the FK506-binding protein also inhibits the release of 
inflammatory mediators from mast cells and basophils.19 We 
have shown that for the eyes suffering from ABC, topical Trl 
was very effective in reducing inflammatory cells, especially 
eosinophils, as shown in conjunctival cytology.23Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Since 1990, our first-line therapy in severe atopic 
blepharitis has been Cn inhibitor Trl or weaker Prl ointment. 
In severe and chronic allergic conjunctivitis, the continuous 
corticosteroid therapy should be replaced with Cn inhibitor 
drops CsA or Trl, if possible. In therapy-resistant, severe aller-
gic conjunctivitis or rhinoconjunctivitis, the immunotherapy 
should be started early to prevent complications or even the 
development of asthma. With the early treatment, the qual-
ity of life will be improved as does the patients’ therapeutic 
compliance.
Allergen-specific immunotherapy (SIT) is highly 
effective in the treatment of patients with severe allergic 
conjunctivitis/rhinoconjunctivitis or asthma and is recom-
mended by World Health Organization as an essential part 
of allergy management strategy. SIT involves the admin-
istration (usually subcutaneous) of increasing doses of 
allergen in order to achieve a hyposensitization. Monthly 
vaccinations lasting for 3 years are demanding for the 
patient. This therapy may have side effects, even anaphy-
lactic reactions. Therefore, in recent years, other administra-
tion routes have been pursued. Sublingual immunotherapy 
(SLIT) with daily administration at least for 3 years is a new 
promising and safe method of SIT. Both methods gradu-
ally induce a tolerance and decrease the symptoms and the 
need of medication, thus improving the quality of life. The 
duration of this effect is about 10 years in subcutaneous 
immunotherapy (SCIT), and we can assume that it lasts 
about the same time with SLIT.
The mechanism of action in SLIT and SCIT is the same. 
The phenotype of T cells is shifted from Th2 prevalence 
with production of cytokines, interleukins (IL-4, IL-5, IL-13, 
IL-17, and IL-32), to Th1-type response, thus increasing 
IFN-γ and IL-2 production and reducing Th2 activity. This 
is what is believed to happen through anergy or tolerance.24 
T-cell tolerance is characterized by the generation of 
allergen-specific Treg producing IL-10 and transforming 
growth factor-β with immunosuppressant or regulatory 
properties.
Another method of immunomodulation is anti-IgE 
therapy. The anti-IgE antibody (omalizumab) has its effect 
by binding to IgE that is not bound to mast cells and inhibits 
it from binding to mast cells.25 The target diseases are allergic 
rhinoconjunctivitis and asthma. The subcutaneous injections 
are given every 4 weeks or more frequently.
With early, intensive, and long-enough therapy, the 
destructive inflammatory processes can be slowly turned 
off, and in best cases, the therapy can be stopped or at least 
reduced.
Acute allergic conjunctivitis
SAC is the most common allergic disease in the eye 
(Figure 1). It is also called hay fever conjunctivitis. SAC is 
usually caused by pollen, and the symptoms are limited to the 
season. Some patients may have exacerbations of symptoms 
around the year, for example from animals, mites, and more 
rarely foods or molds.
Itching of the eyes is the most characteristic symptom of 
SAC. Other symptoms include tearing, burning sensation, 
and photophobia. SAC is usually bilateral. The signs con-
sist of mild papillary hypertrophy of the tarsal conjunctiva, 
  redness, lid and/or conjunctival edema, and chemosis.
It is important that the therapy should be started immedi-
ately, sufficiently, and for long enough, that is, throughout the 
season until all the symptoms have disappeared. The goal is 
to prevent transformation of SAC to a chronic inflammation. 
It is important to also treat the possible concomitant rhinitis 
or asthma symptoms.
In the treatment of SAC, antihistamines are effective. 
Tablets are more effective than drops in coincident rhinitis 
symptoms. Sometimes in the acute stage, local corticosteroids 
are needed. The treatment should be continued with mast 
cell stabilizers including sodium chromoglycate, nedocro-
mil, or lodoxamide eyedrops (Table 1). There may be also 
a mild lid eczema, which can be treated with a short-term 
corticosteroid ointment.
In most cases, SAC is not serious. However, it may be 
very disturbing to patients, can affect their quality of life, 
and can have significant socioeconomic impact. In more 
serious cases where an appropriate local therapy has failed, 
immunotherapy is a good choice. Until recently, only SCIT 
with injections was available,26 but now, a new and more 
comfortable option, SLIT, has become available.27–29 In both 
these forms of immunotherapy, the ocular symptoms usually 
Figure 1 Acute allergic conjunctivitis.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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subside first. The effect of SCIT usually lasts for 7–10 years. 
The SCIT must be started outside the season. It demands 
regular monthly injections, which must be started at lower 
concentrations and increased gradually to the maintenance 
doses. Anaphylactic reactions are possible, and therefore the 
injection must be given in places where the staff is educated 
to treat anaphylactic reactions.
SLIT is available at least to grass pollens, for example, 
timothy, ragweed, and to birch pollen, house dust mite, 
and latex. The advantage of SLIT is that the tablets can be 
taken at home. The tablets can be taken daily for 3 months 
  (preseasonal) to 3 years. SLIT is not as effective as SCIT, but 
randomized, double-masked studies are lacking. Side effects 
of SLIT are usually harmless, but some anaphylactic reac-
tions have been described in the literature.30 The duration of 
the effect after cessation of SLIT is not known. In severe and 
polysensitized rhinoconjunctivitis cases, a combination of 
SLIT or SCIT with anti-IgE antibody therapy   (omalizumab) 
may be beneficial.31
Chronic allergic conjunctivitis
PAC
The allergy panel of patients with PAC (Figure 2) often 
shows allergy to animals and mites. The symptoms and signs 
are much the same as in SAC, but they are usually milder. 
This condition affects all age groups but mostly young and 
middle-aged people of both sexes.
PAC is often connected with dry eye, which has an impact 
on therapy. The therapy should be started without delay, 
intensive enough, and for long enough. Milder cases can be 
treated with topical mast cell stabilizers, which should be 
without preservatives. A common preservative in topical 
medications, benzalkonium chloride, may occasionally cause 
ocular allergies. More harmful is its toxicity to the inflamed 
conjunctiva, and it may worsen the already   existing dry eye. 
Sodium chromoglycate or lodoxamide drops 3–4 times daily 
may be helpful in mild dry eye symptoms. Antihistamines 
are not suitable for long-term use because they can worsen or 
even cause dry eye. However, they can be used for short terms 
as an additive medication. In more severe cases, topical ste-
roids are needed for short terms as pulse therapy.   Pre-existing 
other allergic symptoms including rhinitis, asthma, or atopic 
dermatitis should be treated appropriately.
ABC
ABC (Figure 3) is a serious and often chronic eye disease 
(Figure 4). The patients typically have atopic eczema in the 
face and eyelids. This disease more often affects boys and 
men. The patients with ABC often have high serum IgE lev-
els, which may be several thousand IU per   milliliter. These 
patients are in many cases multiallergic, that is, they have 
several positive skin prick tests to common   environmental 
allergens.
Table 1 Topical treatment schedule for eosinophilic allergic and 
eosinophilic nonallergic conjunctivitis
Treatment Allergic Nonallergic
Antibiotics No in the beginning
Corticosteroids or 
corticosteroids–antibiotics
Not usually or short- 
term
First step/later 
when symptoms 
persist
Antihistamines Yes Not usually  
or short term
Mast cell stabilizers Yes Yes
Astringents Not usually No
Lubricants Sometimes Yes
immunotherapy in severe cases No
Nonsteroidals (NSAiD) Seldom Yes
immunosupressants 
(cyclosporine and tacrolimus)
No Yes
Duration of topical 
treatment
Short term Long term Figure 2 Chronic allergic conjunctivitis.
Figure 3 Atopic blepharoconjunctivitis in a child.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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The symptoms of ABC include intense itching, photo-
phobia, epiphora, and occasionally blurred vision. The signs 
consist of red and swollen lids often with rhagades, lost eye-
lashes, and red and swollen tarsal conjunctiva with   papillary 
hypertrophy. In worst cases, a serious corneal ulcer may 
lead to vision-disturbing scars or even to ocular   penetration. 
These ulcers are dangerous because in ABC, the skin of the 
eyelids and the conjunctiva mostly show Staphylococcus 
aureus infection.
The topical treatment for ABC consists of different ste-
roid preparations. Now a new product, calcineurin inhibitor 
tacrolimus, which was first used for the treatment of atopic 
dermatitis, has been shown to be very useful in the treatment 
of ABC. We are among the first to use Trl ointment in the 
treatment of atopic lid eczema 10 years ago.23 Since then we 
have seen very good results without any serious side effects 
in this treatment.32
The treatment of ABC must be divided into two parts: 
lid skin care and treatment of conjunctivitis. In short-term 
lid therapy, corticosteroid ointments are a good choice. 
In long-term treatment, the side effects of corticosteroids are 
obvious: possible corticosteroid-induced glaucoma, cataract, 
or atrophy of the lid skin. With Trl 0.03% ointment or with 
another Cn inhibitor 1% Prl, the treatment is safe without 
any serious side effects, even in children.23,32,33 The Trl oint-
ment is usually applied to the lids at night for 2 weeks or 
more until the eczema has healed. When the symptoms have 
subsided, the treatment can be stopped or it can be continued 
in milder cases for 2–3 times a week. The remission period is 
substantially longer than that with corticosteroid treatment. 
Trl ointment seems to be very safe and can be continued for 
a longer time regularly or intermittently. Weaker Prl at the 
beginning must be applied 2 times daily but later on once 
daily is sufficient.
vKC
VKC (Figure 5) is a relatively rare chronic disease, which 
mainly affects children and young adolescents. The 
majority of patients are boys, with a male:female ratio of 
3:1. The disease usually begins at the age of 6–10 years. 
Only about 60% are atopic. VKC is often complicated 
by keratitis and corneal ulcers, which may cause visual 
disability.
Main symptoms of VKC are intense itching and photo-
phobia. The signs include redness, lid swelling, inflammatory 
ptosis, ropy discharge, and eosinophilic granulomas as giant 
papillae on the upper tarsal plate. The conjunctival cytolology 
in patients with VKC shows a great amount of eosinophils 
and other inflammatory cells.
The treatment of VKC may last from months to several 
years depending on severity of the disease. The mainstay 
of the therapy is mast cell-stabilizing drops. In relapses, a 
topical corticosteroid pulse therapy is needed. When the 
need of corticosteroids is almost continuous, CsA eyedrops 
0.05% or 0.1% are needed. CsA 0.1% aqueous ophthal-
mic solution twice daily is an effective and safe topical 
medication in the treatment of VKC.34 We have used the 
same strength of CsA solution for children in Helsinki 
University Skin and Allergy Hospital for 10 years without 
any serious side effects (unpublished data). In Japan, Trl 
ophthalmic suspension 0.1% twice daily was very effec-
tive in the treatment of severe allergic conjunctivitis.35 We 
have used Trl 0.01% eyedrops in ricin oil vehicle twice 
daily in the treatment of severe allergic conjunctivitis 
both for children and adults. This treatment was effec-
tive, but many of our patients showed marked side effects 
including burning and irritation. The ricin oil vehicle may 
have caused these symptoms especially in patients with   
a dry eye.
Figure 4 Severe atopic blepharoconjunctivitis.
Figure 5 vernal keratoconjunctivitis.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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NAEC
NAEC (Figure 6) seems to be poorly known in clinical 
practice as the presence of eosinophils is usually regarded 
as a sign of allergy.6,7,36 The condition may be analogous 
to the nonallergic eosinophilic rhinitis6,37 and nonallergic 
eosinophilic asthma.38 The majority of patients are middle-
aged or older women. Their skin prick tests are negative, 
serum IgE is normal, and they have no atopic eczema. How-
ever, these patients often have dry eye.
The symptoms of NAEC include itching, foreign body 
sensation, lacrimation, slight discharge, and minimal lid 
swelling. Signs consist of eosinophilia in conjunctival 
cytology (Figure 7), at least (1+) on the semiquantitative 
scale.39
In the treatment of NAEC, we have successfully used 
hydrocortisone-containing eyedrops for 1–2 weeks and 
continued with topical mast cell-stabilizers including chro-
moglycate, nedocromil, or lodoxamide or with nonsteroidal 
anti-inflammatory drugs including topical diclofenac. 
Because of the common coexisting dry eye, the preservative-
free mast cell-stabilizing agents are recommended. Long-
term use of topical or systemic antihistamines should be 
avoided because of their drying effects. Additive short-term 
use of corticosteroids is often needed. Moistening drops are 
added as needed. In severe cases, CsA eyedrops can be used 
(Table 1). Due to the chronicity of NAEC, the duration of 
the therapy varies from months to years.
Contact allergic 
blepharoconjunctivitis
Contact allergic blepharitis (Figure 8) and contact aller-
gic blepharoconjunctivitis (CABC) are common. In a 
German study, the predominant causes were allergic 
contact dermatitis (44%), atopic eczema (25%), air-
borne contact dermatitis (10%), and irritant contact   
dermatitis (9%).40
Contact dermatoconjunctivitis is a typical contact 
T-cell-mediated delayed hypersensitivity reaction to haptens, 
which become immunogenic only after they bind to tissue pro-
tein. Typical delayed type of allergies, the symptoms of which 
may be only in the eyelids, are nail lacquer and mascara   allergies 
and the components of eyedrops and ointments. The most 
common place in nail lacquer allergies is just the eyelids. The 
sensitizer is often the toluensulfonamide–formaldehyde resin. 
The main allergen in mascara is natural resin, which is used 
in most mascara as adhesive. The lid mascara often contains 
nickel and cobalt (blue color), which may cause lid eczema 
for those who are already   sensitized and the mascara may also 
itself sensitize the users.
All eyedrops and ointments contain allergens, for 
example antibiotics including neomycin, framycetin, sulfa, 
chloramphenicol, and (oxy) tetracycline; glaucoma medi-
cations, including pilocarpine, beta blockers, brimonidine, 
apraclonidine, dorzolamide, and prostaglandin deriva-
tives; local anesthetics; antihistamines; anticholinergics; 
the preservatives benzalkonium chloride and thimerosal; 
mydriatics including scopolamine, atropine, tropicamide, 
phenylephrine hydrochloride, and cyclopentolate hydro-
chloride. These agents can cause very angry allergic reac-
tions which may last a long time and cause, especially in 
glaucoma therapy, a common intolerance to all topical 
glaucoma medication. In addition, contact lens care solu-
tions, for example chlorhexidine and papain, can cause 
Figure 6 Nonallergic eosinophilic conjunctivitis. Figure 7 Conjunctival cytology.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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robust allergic reactions. These allergic reactions manifest 
almost always as blepharoconjunctivitis, which means that 
besides lid eczema, there is also conjunctivitis.
Many different substances can cause symptoms both in 
the eyelids and in other skin parts of the body, but the thin 
skin of the eyelids is the most sensitive. Frames of eyeglasses 
that contain plastics and metal may cause eczema both in the 
contact area and lid and face.
Delayed type of allergy is caused by many components 
that spread as aeroallergens and can cause lid or face eczema. 
These allergens include rubber chemicals, some greenhouse 
plants, and the lactones of composites.
Skin prick tests and epicutan tests are diagnostics of lid 
eczema. It is important to test also with the patient’s own 
materials, because the standard test series cover poorly the 
allergens which cause lid eczema. Atopic and seborrheic lid 
eczema (Figure 9) resemble each other. Skin tests help to 
make the right diagnosis.
In the treatment of CABC, it is most important to clarify 
the causing agent and to eliminate it. Allergic lid eczema 
heals also without therapy when the allergen is avoided. 
The healing process may be sped up by using mild corti-
costeroid ointment on the lids for a few days. Sometimes 
antihistamines are needed for a short time against intense 
itching.
Atopic blepharitis is often chronic and needs longer 
therapy. In the treatment, corticosteroid ointments can be 
used for a short time. In chronic atopic blepharitis, we can 
now use a very effective and safe corticosteroid-replacing 
therapy, Trl ointment (Protopic®). It has two concentra-
tions: 0.1% and 0.03%. We have used during the last 10 
years Trl 0.03% ointment on the lids in children without 
any serious side effects. It does not cause skin atrophy, 
cataract, or glaucoma as long-term corticosteroid treat-
ment does.18,26 Weaker Prl (Elidel®) in 1% concentration is 
another   corticosteroid-replacing therapy for lid eczema.
Summary
Allergic conjunctivitis is common and occurs generally 
in both eyes. It may appear as the first step of the allergic 
cascade. It should be treated early, effectively, and for long 
enough to prevent worsening of the eye symptoms and 
spreading of the allergic inflammation to the airways.
In the treatment, we may raise the tolerance against 
natural allergens with SCIT or SLIT. The other way is to 
regulate and minimize the tissue destruction, especially in 
chronic allergic inflammation, with corticosteroid replacing 
immunomodulating therapies.
In severe SAC, SCIT or SLIT are recommended. The 
more common slight forms are treated with antihistamines 
and/or mast cell-stabilizing agents. It is important to treat 
simultaneously often concomitant rhinitis or asthmatic 
symptoms.
In chronic allergic conjunctivitis and NAEC, mast 
cell-stabilizing agents are recommended. Preservative-free 
drops should be preferred. The often concomitant dry eye 
often becomes worse with long-standing antihistamine 
therapy. Short-term corticosteroids are often needed addi-
tionally. More severe cases may need Cn inhibitors such 
as CsA drops. Dry eye often needs additional artificial 
tears.
In the more severe forms of VKC and ABC, the 
inflammation needs often long-standing therapy for which 
corticosteroid-replacing therapies are recommended. In 
VKC, corticosteroids should be replaced with Cn inhibi-
Figure 9 Seborrheic blepharitis.
Figure 8 Contact allergic blepharoconjunctivitis (pilocarpine eyedrops).Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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tors such as CsA drops. The mainstay of therapy is mast 
cell-stabilizing agents. Antihistamines alone are not rec-
ommended, but they can be used periodically combined 
with mast cell-stabilizing agents. Sometimes additional 
short-term steroid therapy is needed. Severe ABC is treated 
like VKC, but ABC patients may need lubricating drops 
additionally for dry eye.
The concomitant and often severe blepharitis must be 
treated simultaneously with corticosteroid-replacing Cn 
inhibitors. Trl 0.03% ointment once daily is very effective. 
Weaker Prl 1% is applied at the beginning twice daily; later, 
once daily is sufficient. Chronic atopic blepharitis should 
be treated in the first line with Cn inhibitors, which can be 
used intermittently or continuously. If these are not tolerated, 
minimized corticosteroid therapy can be used. 
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